Market Forecast by Countries (United States, Canada), By Product (RB51 Vaccine Strain, S19 Vaccine Strain, Others), By Application (Sheep, Pigs, Cattle, Others) And Competitive Landscape
Product Code: ETC182116 | Publication Date: May 2021 | Updated Date: Mar 2025 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 200 | No. of Figures: 90 | No. of Tables: 28 | |
Report Name | North America Brucellosis Vaccines Market |
Forecast Period | 2025-2031 |
Market Size | USD 24.36 billion by 2031 |
CAGR | 7.2% |
Growing Sector | Livestock Farming and Animal Husbandry |
North America Brucellosis Vaccines Market report thoroughly covers the market By Countries, By Type, and By Application The market outlook report provides an unbiased and detailed analysis of the ongoing market trends, opportunities/high growth areas, and market drivers which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.
North America Brucellosis Vaccines Market was valued at USD 17.65 billion and is expected to reach USD 24.36 billion , growing at a CAGR of around 7.2% from 2025-2031. The growing demand for meat products, increasing prevalence of brucellosis in livestock, and rising government initiatives to control the spread of the disease are some of the key factors driving the growth of this market.
North America Brucellosis Vaccines Market is witnessing a significant growth, stimulated by the rising incidence of Brucellosis in livestock across the continent. This demand is further fueled by the increasing awareness among livestock farmers about the benefits of vaccination in preventing the economic losses associated with the disease.
According to 6Wresearch, the North America Brucellosis Vaccines Market size is expected to grow, reaching at a CAGR of 7.2% during the forecast period of 2025-2031. A significant driver is the increasing incidence of brucellosis in livestock, necessitating widespread vaccination programs to curb its spread. Also, the initiatives taken by the government and awareness campaigns around livestock health are bolstering the North America Brucellosis Vaccines Market Growth and overall demand for effective vaccines.
However, the market faces restraints such as the high cost of vaccination and logistical challenges in distributing vaccines across remote areas. Despite this, the development of more affordable and thermally stable vaccines that can withstand North America's varied climatic conditions, aiming to make vaccination programs more accessible and effective across the continent. Moreover, innovations in biotechnology and partnerships between governments and private entities are set to play a crucial role in overcoming these challenges, paving the way for significant market expansion.
The North America Brucellosis Vaccines Market is witnessing several novel trends that are expected to have a significant impact on market growth. One major trend is the adoption of advanced technologies in vaccine development, such as nanotechnology and recombinant DNA technology, leading to the production of more effective and affordable vaccines. Additionally, there is a growing focus on developing multivalent vaccines that can protect against multiple strains of brucellosis, reducing the need for separate vaccinations. Another emerging trend is the use of oral vaccines for livestock, which eliminates the need for injections and reduces stress on animals during vaccination.
The North America Brucellosis Vaccines Market presents lucrative investment opportunities due to the increasing demand for vaccines and technological advancements in vaccine development. The rise in collaborations between government bodies, research institutes, and pharmaceutical companies also creates potential investment avenues for new entrants in the market. Furthermore, the growing focus on livestock health and awareness campaigns by governments present an opportunity for investors to support research and development initiatives aimed at improving vaccine efficacy.
The North America Brucellosis Vaccines Market is highly competitive, with the presence of several key players such as Merck Animal Health, Boehringer Ingelheim GmbH, and Zoetis Inc. These companies are investing in research and development to launch innovative products and expanding their product portfolio through collaborations and partnerships. For instance, in 2020, Merck Animal Health collaborated with Georgia Biomedical Partners to develop a novel vaccine candidate for brucellosis. Such developments are expected to drive market growth and increase competition within the industry.
Brucellosisis a bacterial infection that can affect both humans and animals. It is caused by the bacteria Brucella and can be transmitted through direct contact with infected animals or consumption of contaminated animal products. In North America, the most commonly affected species are cattle, bison, elk, and pigs.Due to its potential impact on public health and economic losses in the livestock industry, governments in North America have implemented regulations to control and eradicate brucellosis. These regulations include mandatory testing and vaccination of livestock herds, as well as strict biosecurity measures.
In the United States, the United States Department of Agriculture (USDA) has a brucellosis eradication program in place, which includes targeted testing and vaccination of cattle herds in high-risk areas. Similarly, Canada also has a national Brucellosis Eradication Program managed by the Canadian Food Inspection Agency (CFIA).
The North America brucellosis vaccines market is expected to experience significant growth in the coming years. This can be attributed to the increasing awareness about animal health and the need for effective vaccination programs. Governments across North America have also implemented strict regulations for the prevention of brucellosis, which has further fueled the demand for vaccines.One key factor driving the growth of this market is the rising incidence of brucellosis in livestock animals such as cattle, goats, and pigs. This highly contagious disease not only affects animal health but also poses a threat to human health through the consumption of infected animal products.
The report offers a comprehensive study of the subsequent market segments and their leading categories.
The US is expected to dominate the North America Brucellosis Vaccines Market owing to the increasing incidence of brucellosis in livestock and the government's initiatives for disease control. The country is also a major consumer of meat products, further driving demand for efficient vaccination programs.
The RB51 vaccine strain is expected to dominate the market owing to its high efficacy and availability in multiple forms, such as oral and intramuscular vaccines. This type of vaccine is also more affordable compared to other strains, making it a preferred choice among livestock farmers.
Cattle is expected to dominate the market due to the high prevalence of brucellosis in this species and the significant economic losses associated with the disease. Additionally, government initiatives for cattle health are also expected to drive demand for vaccination programs.
The report offers a comprehensive study of the subsequent market segments
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Brucellosis Vaccines Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Brucellosis Vaccines Market Revenues & Volume, 2021 & 2031F |
3.3 North America Brucellosis Vaccines Market - Industry Life Cycle |
3.4 North America Brucellosis Vaccines Market - Porter's Five Forces |
3.5 North America Brucellosis Vaccines Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Brucellosis Vaccines Market Revenues & Volume Share, By Form, 2021 & 2031F |
3.7 North America Brucellosis Vaccines Market Revenues & Volume Share, By Form, 2021 & 2031F |
3.8 North America Brucellosis Vaccines Market Revenues & Volume Share, By , 2021 & 2031F |
3.9 North America Brucellosis Vaccines Market Revenues & Volume Share, By , 2021 & 2031F |
4 North America Brucellosis Vaccines Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Brucellosis Vaccines Market Trends |
6 North America Brucellosis Vaccines Market, 2021 - 2031 |
6.1 North America Brucellosis Vaccines Market, Revenues & Volume, By Product, 2021 - 2031 |
6.2 North America Brucellosis Vaccines Market, Revenues & Volume, By Application, 2021 - 2031 |
7 United States Brucellosis Vaccines Market, 2021 - 2031 |
7.1 United States Brucellosis Vaccines Market, Revenues & Volume, By Product, 2021 - 2031 |
7.2 United States Brucellosis Vaccines Market, Revenues & Volume, By Application, 2021 - 2031 |
8 Canada Brucellosis Vaccines Market, 2021 - 2031 |
8.1 Canada Brucellosis Vaccines Market, Revenues & Volume, By Product, 2021 - 2031 |
8.2 Canada Brucellosis Vaccines Market, Revenues & Volume, By Application, 2021 - 2031 |
9 North America Brucellosis Vaccines Market Key Performance Indicators |
10 North America Brucellosis Vaccines Market - Opportunity Assessment |
10.1 North America Brucellosis Vaccines Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Brucellosis Vaccines Market Opportunity Assessment, By Product, 2021 & 2031F |
10.3 North America Brucellosis Vaccines Market Opportunity Assessment, By Application, 2021 & 2031F |
10.4 North America Brucellosis Vaccines Market Opportunity Assessment, By , 2021 & 2031F |
10.5 North America Brucellosis Vaccines Market Opportunity Assessment, By , 2021 & 2031F |
11 North America Brucellosis Vaccines Market - Competitive Landscape |
11.1 North America Brucellosis Vaccines Market Revenue Share, By Companies, 2024 |
11.2 North America Brucellosis Vaccines Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Company Profiles |
13 Recommendations |
14 Disclaimer |